Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
Researchers compared outcomes between babies born to HIV-positive mothers exposed to antiretrovirals and those who were not.
Timothy Brown may have company after a man’s virus went into remission following an HIV-resistant stem cell transplant to treat his cancer.
Previous studies found Tivicay monotherapy was subpar, but this trial switched people to the drug who had started combo treatment early.
Research in human cells and mice found the antiretroviral suppressed harmful chronic inflammation linked to age-related disorders.
In clinical trials, the single-tablet regimen of Tivicay (dolutegravir) and Epivir (lamivudine) was as effective as a three-drug treatment.
A speedy overview of the major scientific findings presented at the International AIDS Conference in Amsterdam (AIDS 2018)
Full 48-week results comparing dolutegravir plus lamivudine with a three-drug combo were presented at the International AIDS Conference.
The combo of dolutegravir and lamivudine controlled HIV as well as a triple-drug combo of dolutegravir plus Truvada.
The new drug application is for doravirine as both an individual tablet and part of a combination tablet.
In four studies, this two-drug combination suppressed the virus as effectively as staying on a three-drug regimen.
Highlights from the research presented at the 9th International AIDS Society Conference on HIV Science in Paris.
Such generic drugs could save nations huge sums in the coming years.
An unacceptably high rate of mother-to-child transmission of HIV still occurs in many African nations, often through breast feeding.
The trial will test a regimen of Tivicay (dolutegravir) plus Epivir (lamivudine) against Tivicay and Truvada (tenofovir/emtricitabine).
The regimen of Tivicay (dolutegravir) and Epivir (lamivudine) would be a highly cost-effective first-line option and save a great deal.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.